BRIEF-Seres Therapeutics says to begin SER-262 Phase 1b study in mid-2016

* Seres Therapeutics presents new data at ASM Microbe 2016,

including characterization of SER-262, the rationally-designed,

fermented microbiome therapeutic candidate for primary

clostridium difficile infection

Read more